hyperkalaemia

This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.

AZ finally gets EU nod for Veltassa rival Lokelma

AZ finally gets EU nod for Veltassa rival Lokelma. And expects a US FDA verdict for the hyperkalaemia treatment later this year. ... The approval of Lokelma “addresses a significant unmet need by bringing a rapid and sustained therapeutic option for

Latest news

Vifor wins European approval for Veltassa

Vifor wins European approval for Veltassa. European Commission approves the drug to treat hyperkalaemia. ... The European Commission (EC) has approved Vifor’s Veltassa (patiromer) to treat adults with hyperkalaemia, a potentially life threatening
FDA turns down AZ's ZS-9 once again on manufacturing issues

The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an ... Veltassa was launched in early 2016 - becoming
AZ nears EU approval for hyperkalaemia drug Lokelma

AZ nears EU approval for hyperkalaemia drug Lokelma. CHMP adopts positive opinion for the potassium-binding treatment. ... Hyperkalaemia is commonly associated with chronic heart failure and chronic kidney disease, and carries risk of potentially fatal
2017 set to be a "defining year" for AZ

and hyperkalaemia candidate sodium zirconium cyclosilicate (ZS-9), which was rejected by the FDA last year and re-filed.
Rare disease therapies head the ‘class of 2015’

parathyroid hormone replacement. Shire. USA. patiromer. Veltassa. hyperkalaemia. potassium ion binder.

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Deal Watch July 2016

for the treatment of hyperkalaemia.
Deal Watch November 2015

Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,
Pharma deals during October 2013

Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager – Med Comms – Kent: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Programme Executive: Salary TBC

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Manager / Account Director: Great salary and bebefits

Senior Medical Writer: Great salary and bebefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

Project Manager, Medical Communications, London: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Medical Writer - (London, Brighton or Copenhagen): Competitive

Project Manager, Medical Communications, Oxford: Excellent Salary

Editor – Medical Education Agency – Bucks: Salary TBC

Account Manager – Med Comms – London: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Medical Writer, e-learning/ training, London: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Subscribe to our email news alerts

PMHub

Add my company

Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...